[HTML][HTML] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, AC Green… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
[HTML][HTML] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, ACA Green, HJ Curtis… - The Lancet Regional …, 2023 - Elsevier
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, AC Green… - The Lancet Regional …, 2023 - europepmc.org
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
[HTML][HTML] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, ACA Green… - The Lancet Regional …, 2023 - ncbi.nlm.nih.gov
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab… - The Lancet …, 2023 - researchonline.lshtm.ac.uk
Background: Timely evidence of the comparative effectiveness between COVID-19
therapies in real-world settings is needed to inform clinical care. This study aimed to …
therapies in real-world settings is needed to inform clinical care. This study aimed to …
[PDF][PDF] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, ACA Green, HJ Curtis… - Health, 2023 - scienceopen.com
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
B Zheng, J Tazare, L Nab, AC Green… - The Lancet Regional …, 2023 - europepmc.org
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …